Japan

Nichi-Iko Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Japan Approves Dexamethasone as Coronavirus Treatment

Lead Product(s): Dexamethasone

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2020

Details:

The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.

Otsuka Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

Lead Product(s): Delamanid

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.

Daiichi Sankyo Co Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Daiichi Sankyo, Kitasato Pharma to terminate sales cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan

Lead Product(s): Influenza HA Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: Kitasato Pharmaceutical

Deal Size: Undisclosed Upfront Cash: $3.5 million

Deal Type: Agreement March 27, 2020

Details:

After a review of sales strategy and discussions, the companies have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Nichi-Iko Pharmaceutical

Japan Approves Dexamethasone as Coronavirus Treatment

Otsuka Pharmaceutical

Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

Daiichi Sankyo Co Ltd

Daiichi Sankyo, Kitasato Pharma to terminate sales cooperation for Influenza HA Vaccine “Daiichi Sankyo” in Japan